Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Account Payables
Amounts the company owes suppliers for goods and services received.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 320.4% from a year ago
Account payables stood at $10.02M at the end of Q1 FY2026, up 320.4% from a year earlier and up 77.6% from the prior quarter. Over 3 fiscal years it compounded at +35.6% a year.
Context
- Account payables amounted to 5.2% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +320.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5.65M USD
- Year-over-year change
- +192.2%
- 4-year CAGR
- +6.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.65M | +192.2% |
| FY2024 | 2024-12-31 | 1.93M | -51.5% |
| FY2023 | 2023-12-31 | 3.98M | +75.9% |
| FY2022 | 2022-12-31 | 2.26M | -48.4% |
| FY2021 | 2021-12-31 | 4.38M | — |
Account Payables vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +320.4% is the highest of 8, against a peer median of -43.6%.
- Account payables amounts to 5.2% of total assets for MIST, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €15.04M EUR | +89.8% | +3.3% | 24.0% | |
| Mar 2026 | $10.02M USD | +320.4% | +35.6% | 5.2% | |
| Mar 2026 | $5.48M USD | +51.0% | +60.5% | 11.1% | |
| Mar 2026 | CHF 1.92M CHF | -19.9% | -2.0% | 2.2% | |
| Mar 2026 | $858K USD | -43.6% | -40.4% | 1.7% | |
| Mar 2026 | $622K USD | -77.0% | -15.5% | 0.4% | |
| Mar 2026 | $435K USD | -89.3% | +0.6% | 0.3% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $272K USD | -93.3% | -37.9% | 1.2% |
| Peer median (excluding MIST) | — | -43.6% | -2.0% | 1.7% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.14M | 7.64M | 13.76M | 25.31M | 73.05M |
| Short-term Investments | 0 | 56.95M | 52.24M | 44.38M | 32.91M |
| Net Receivables | 483K | 1.21M | 3.85M | 2.39M | 3.51M |
| Inventory | 0 | 0 | 0 | 0 | 648K |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 118.92M | 71.8M | 73.03M | 73.93M | 111.92M |
| Property, Plant & Equipment (Net) | 926K | 2.68M | 2.19M | 1.57M | 1.64M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 926K | 2.68M | 2.19M | 1.57M | 1.64M |
| Total Assets | 119.85M | 74.48M | 75.23M | 75.5M | 113.56M |
| Account Payables | 4.38M | 2.26M | 3.98M | 1.93M | 5.65M |
| Short-term Debt | 224K | 495K | 0 | 0 | 647K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 709K | 808K | 1.99M | (0) | 5.23M |
| Total Current Liabilities | 6.78M | 6.14M | 7.23M | 8.13M | 13.98M |
| Long-term Debt | 0 | 0 | 49.77M | 53.35M | 57.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 83K |
| Total Non-current Liabilities | 474K | 2M | 51.23M | 54.23M | 57.81M |
| Total Liabilities | 7.25M | 8.14M | 58.46M | 62.35M | 71.79M |
| Common Stock | 251.9M | 273.9M | 260.5M | 288.05M | 352.62M |
| Retained Earnings | (206.32M) | (266.34M) | (326.03M) | (367.55M) | (430.6M) |
| Accumulated OCI | 51.31M | 34.35M | 48.46M | 53.08M | 55.65M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 112.6M | 66.35M | 16.77M | 13.15M | 41.77M |
| Total Debt | 698K | 2.49M | 51.78M | 54.8M | 58.38M |
| Net Debt | (113.44M) | (5.15M) | 38.02M | 29.48M | (14.67M) |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.